Home
/
Ovid Therapeutics Inc.
/
Financials
/
Quarterly
Ovid Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Ovid Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$132.0K
Nov 12, 2025
Q2
2025
Jun 30, 2025
$6.27M
Aug 13, 2025
Q1
2025
Mar 31, 2025
$130.0K
May 13, 2025
Q3
2025
Sep 30, 2024
$173.0K
Nov 12, 2025
Q2
2025
Jun 30, 2024
$169.0K
Aug 13, 2025
Q1
2025
Mar 31, 2024
$148.0K
May 13, 2025
Q3
2024
Sep 30, 2023
$109.0K
Nov 12, 2024
Q2
2024
Jun 30, 2023
$75.0K
Aug 13, 2024
Q1
2024
Mar 31, 2023
$66.0K
May 14, 2024
Q3
2023
Sep 30, 2022
$11.1K
Nov 3, 2023
Q2
2023
Jun 30, 2022
$0
Aug 4, 2023
Q1
2023
Mar 31, 2022
$1.45M
May 5, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($12.16M)
Nov 12, 2025
Q3
2025
Jun 30, 2025
($4.68M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($4.68M)
Aug 13, 2025
Q2
2025
Mar 31, 2025
($10.24M)
Aug 13, 2025
Q3
2025
Mar 31, 2025
($10.24M)
Nov 12, 2025
Q1
2025
Mar 31, 2025
($10.24M)
May 13, 2025
Q3
2025
Sep 30, 2024
($14.01M)
Nov 12, 2025
Q3
2025
Jun 30, 2024
$8.52M
Nov 12, 2025
Q2
2025
Jun 30, 2024
$8.52M
Aug 13, 2025
Q2
2025
Mar 31, 2024
($11.69M)
Aug 13, 2025
Q3
2025
Mar 31, 2024
($11.69M)
Nov 12, 2025
Q1
2025
Mar 31, 2024
($11.69M)
May 13, 2025
Q3
2024
Sep 30, 2023
($11.25M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($12.41M)
Aug 13, 2024
Q3
2024
Jun 30, 2023
($12.41M)
Nov 12, 2024
Q2
2024
Mar 31, 2023
($13.36M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($13.36M)
May 14, 2024
Q3
2024
Mar 31, 2023
($13.36M)
Nov 12, 2024
Q3
2023
Sep 30, 2022
($11.97M)
Nov 3, 2023
Q3
2023
Jun 30, 2022
($14.59M)
Nov 3, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($12.52M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($5.07M)
Aug 13, 2025
Q1
2025
Mar 31, 2025
($12.55M)
May 13, 2025
Q3
2025
Sep 30, 2024
($13.23M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($20.52M)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($17.42M)
May 13, 2025
Q3
2024
Sep 30, 2023
($12.03M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($14.17M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($14.89M)
May 14, 2024
Q3
2023
Sep 30, 2022
($12.80M)
Nov 3, 2023
Q2
2023
Jun 30, 2022
($14.30M)
Aug 4, 2023
Q1
2023
Mar 31, 2022
($16.27M)
May 5, 2023
Q3
2022
Sep 30, 2021
($11.68M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($14.31M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
$176.56M
May 10, 2022
Q3
2021
Sep 30, 2020
($16.40M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($23.14M)
Aug 16, 2021
Q1
2021
Mar 31, 2020
($20.29M)
May 13, 2021
Q3
2020
Sep 30, 2019
($16.77M)
Nov 13, 2020
Q2
2020
Jun 30, 2019
($13.32M)
Aug 10, 2020